Opinion|Videos|November 18, 2026

Emerging Cell Surface Targets and Neuroendocrine Biomarkers in Prostate Cancer

The panelists look ahead to the biomarkers and targets most likely to change prostate cancer practice.

The panelists look ahead to the biomarkers and targets most likely to change prostate cancer practice. Cell surface antigens beyond prostate-specific membrane antigen (PSMA) represent the biggest frontier, including STEAP1, targeted by the T-cell engager xaluritamig, and human kallikrein 2, targeted by the T-cell engager pasritamig and an actinium-based radionuclide therapy. Some targets may be expressed broadly enough to forgo testing, while antibody-drug conjugates may return the field to tissue staining. In neuroendocrine prostate cancer, biopsy confirms transformation and enables staining for emerging targets such as DLL3, although platinum-based chemotherapy remains standard. The panelists envision rapid multitracer PET imaging that could assess several targets at once and personalize therapy noninvasively. Until then, they caution against forcing patients who do not meet PSMA PET selection criteria into PSMA-directed therapy, given poor outcomes in that group, and encourage clinical trial referral instead. The conversation closes with practical principles for matching each assay to the clinical question being asked.


Related to this article